Lessons from tobacco for today’s policy debates — and why lawmakers should recognize the pattern.
When lawmakers confront new consumer products surrounded by competing claims about safety, science, and regulation, history offers a useful guide—particularly the history of the tobacco industry.
For decades, tobacco companies insisted that concerns about cigarettes were exaggerated. They funded research, employed respected experts, and assured policymakers that the science was still evolving. In 1954, major cigarette manufacturers even took out full-page newspaper advertisements titled “A Frank Statement to Cigarette Smokers,” promising the public that they were committed to investigating the health effects of smoking.
Behind the reassuring language, however, internal documents later revealed a different strategy. The goal was not necessarily to disprove the risks of smoking but to emphasize uncertainty long enough to delay regulation. One tobacco executive memo summarized the approach bluntly:
“Doubt is our product.”
It took decades of litigation and the release of millions of internal industry documents before the full scope of that strategy became clear.
Today, lawmakers across the United States are once again hearing from industry lobbyists, consultants, advocacy groups, and researchers about another controversial consumer product: kratom.
Supporters argue that the product should remain widely available. Critics raise concerns about safety, contamination, and pharmacological effects. Between those positions sits a familiar policy battlefield—one that looks strikingly similar to earlier debates over tobacco, opioids, and other regulated substances.
The comparison does not mean the products themselves are identical. Tobacco’s harms are established by decades of epidemiological research involving millions of people. Kratom research is still evolving and remains more limited.
But the policy arguments and messaging patterns surrounding the product often echo earlier industry debates.
That is why lawmakers should examine not only the claims being made, but who is making them and how those claims are framed.
One of the most important lessons from the tobacco era is that funding relationships matter. Tobacco companies famously funded research organizations and scientists whose work emphasized uncertainty about smoking’s health risks. Many of those researchers testified before regulators and lawmakers while presenting themselves as independent experts.
Modern public health policy now routinely asks a simple question: Who is funding the research and advocacy surrounding a product?
In any policy debate, lawmakers should expect transparency about financial relationships between industry groups, advocacy organizations, consultants, and researchers. Disclosure does not invalidate research, but it helps policymakers properly evaluate competing claims.
Another hallmark of tobacco-era messaging was the repeated claim that the science was not yet settled. When early studies linked smoking to cancer, tobacco companies argued that more research was needed before any regulatory action should occur. This strategy delayed meaningful policy responses for years.
In many modern regulatory debates, including those involving emerging substances, the same theme frequently appears: calls to postpone regulation until additional research is completed.
Scientific uncertainty is a normal feature of early research. But history shows that uncertainty can also be emphasized strategically in policy discussions. For lawmakers, the key question becomes whether uncertainty reflects genuine scientific disagreement or a communication strategy that highlights unresolved questions while minimizing existing evidence.
Tobacco companies also frequently framed proposed regulations as extreme government overreach or the beginning of prohibition. This framing can be powerful in political debates. Lawmakers are understandably cautious about policies that might create black markets or unintended consequences.
Yet public health history shows that many effective policies—warning labels, advertising restrictions, age limits, and retail regulation—were initially described by industry representatives as radical proposals. When evaluating such arguments today, policymakers may benefit from asking whether the proposed policy truly represents prohibition, or whether it is simply standard consumer product regulation.
Expert testimony plays an important role in shaping regulatory decisions. But the tobacco experience demonstrated that expert authority can sometimes mask underlying financial or institutional relationships.
This does not mean that experts participating in policy debates are acting improperly. However, lawmakers should expect full transparency regarding:
Transparency allows policymakers to weigh expert opinions in the proper context.
The tobacco experience ultimately reinforced a central principle of public health policy: regulatory decisions must rely on independent scientific evaluation, not industry messaging.
Government agencies such as the FDA, CDC, and state public health departments exist precisely to provide that independent assessment. Their role is to evaluate safety data, toxicology, adverse events, and population health impacts.
In emerging policy debates, lawmakers often face two competing narratives:
History suggests that careful scrutiny of both perspectives is essential.
The tobacco playbook is not just history — it’s being used today. See how these patterns appear in current kratom industry messaging: